Evaxion reinforces milestone timeline and provides shareholder update

Copenhagen, denmark, july 03, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today issued the following letter to shareholders.

EVAX Ratings Summary

EVAX Quant Ranking